SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Upgraded by Leerink Partnrs

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by research analysts at Leerink Partnrs to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

A number of other research firms also recently issued reports on SABS. Leerink Partners started coverage on shares of SAB Biotherapeutics in a report on Wednesday. They issued an “outperform” rating and a $7.00 target price for the company. HC Wainwright decreased their price objective on shares of SAB Biotherapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Tuesday, July 22nd. Finally, Chardan Capital decreased their price objective on shares of SAB Biotherapeutics from $20.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $9.75.

SAB Biotherapeutics Price Performance

SAB Biotherapeutics stock opened at $2.79 on Wednesday. SAB Biotherapeutics has a 1 year low of $1.00 and a 1 year high of $6.60. The firm has a 50 day moving average price of $2.29 and a 200 day moving average price of $1.88. The company has a market cap of $29.04 million, a price-to-earnings ratio of -0.70 and a beta of 0.54. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.87 and a current ratio of 0.87.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Thursday, August 7th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.27). Sell-side analysts predict that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Northern Trust Corp acquired a new position in shares of SAB Biotherapeutics during the fourth quarter worth $43,000. Silver Oak Securities Incorporated acquired a new position in shares of SAB Biotherapeutics during the first quarter worth $30,000. Finally, HB Wealth Management LLC lifted its position in shares of SAB Biotherapeutics by 10.9% during the first quarter. HB Wealth Management LLC now owns 263,200 shares of the company’s stock worth $358,000 after purchasing an additional 25,800 shares in the last quarter. 7.82% of the stock is owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.